Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes
about
Plant Viruses as Nanoparticle-Based Vaccines and AdjuvantsPeripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in miceOne-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice.Antigen vehiculization particles based on the Z protein of Junin virus.A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measlesIn vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.Divergence of primary cognate B- and T-cell proliferative responses to subcutaneous and intravenous immunization with virus-like particlesDose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles.Improvement of different vaccine delivery systems for cancer therapy.Bacterial superglue enables easy development of efficient virus-like particle based vaccines.Comparison of Models for Bubonic Plague Reveals Unique Pathogen Adaptations to the Dermis.A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV.Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7.Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responsesDevelopment of virus-like particles for diagnostic and prophylactic biomedical applicationsAssessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.In vitro controlled release of antigen in dendritic cells using pH-sensitive liposome-polymeric hybrid nanoparticles.The route of Leishmania tropica infection determines disease outcome and protection against Leishmania major in BALB/c miceRotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.Targeted immunomodulation using antigen-conjugated nanoparticles.Fluorosomes: fluorescent virus-like nanoparticles that represent a convenient tool to visualize receptor-ligand interactions.Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.Virus-like particle vaccine confers protection against a lethal newcastle disease virus challenge in chickens and allows a strategy of differentiating infected from vaccinated animalsEngineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy.Virus-based nanoparticles as platform technologies for modern vaccines.Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology.Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates.Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections.Optimization of norovirus virus-like particle production in Pichia pastoris using a real-time near-infrared bioprocess monitor.Adjuvant effect of B domain of staphyloccocal protein A displayed on the surface of hepatitis B virus capsid.Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence.Fc microparticles can modulate the physical extent and magnitude of complement activity.Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.Nanoparticle Vaccines Against Infectious Diseases
P2860
Q26782569-B3A9431E-D8F9-491D-A17C-8C47CAA89DDAQ28486624-881E6C46-7D65-460D-87D1-66E7BAA3A405Q30355863-9B3EBE7F-C36E-401C-96D6-16B8FC5A1663Q30391402-AE96A0A4-F766-4475-91F7-93B77B52A986Q31106232-E693FC0E-25C4-4CB3-9AE9-13AF6A0DDB28Q33769306-0F3FEBB9-F6E2-4533-86B4-6991D70B2478Q33931622-244617BC-8B6A-4FA6-B418-BDE728D56024Q34102311-3BE03D27-8588-42C1-9513-049BB26C251EQ34288194-29487DA5-3586-49C4-847C-F04BD3CB2AFCQ34506877-2371F785-9720-42D0-93C9-064EAE29FA0DQ34523734-D5564602-7550-4810-8613-DC89E2147C96Q35745620-D776EA2F-6F2C-461B-B8F7-835A9228A74DQ35757125-EEE3D556-DDE9-4A37-BA7A-FFCF883CE778Q35826994-BEA30403-1E20-457B-8FB4-4867FD967C8EQ35883016-4DE20E0A-ACBD-476F-86D7-2D92D357A2A9Q35889469-340AC0EF-E4A7-4EBE-B66A-5EB84BCB59F0Q36155247-2B975FEA-0C1F-495A-8DC7-B9826E43AD88Q36207818-58C86BE2-52DD-44F3-802D-30D03FB67FD4Q36326918-7C84691F-4C85-4212-A29B-7A1F127169E9Q36655180-525BF254-4870-4AEA-82FD-18B0D4BA9328Q37135255-454AD0F5-0636-4BD4-812A-32C42F2318B7Q37705215-E69777E0-DBCD-4C63-959C-1A8A078FCED8Q38123692-19FC768E-F0CF-40AA-AD37-180A7D2A71A5Q38297557-48667B21-2E38-47F3-A1B2-3BAA12EC6599Q38320531-12E0932D-5779-4DCD-8F98-E786C41D63B5Q38613355-F486E0D6-EDA0-4D30-BB0C-88DD4ED4F25FQ38702017-5513E65C-17A4-4102-A4E8-B3935EFCEDE1Q39068831-94D8C442-F1D7-4C60-8F3D-DF5C825073F2Q40561184-6DB352F3-E4D9-4C12-8346-561375B4300FQ40978948-43B3C716-2E55-4242-A64A-BAA69D429CD9Q40988893-1A4860F8-6972-4479-8722-2C7FB6490969Q41534162-39BA1486-EBE7-459A-BAB4-16A9E4DB9E74Q47324299-242DFCB4-7249-40FE-A4D0-7AF70378B170Q48373815-C2F091F5-07F8-4207-B0FD-65056E26F665Q52655238-C36ACC4B-CFE8-4FAF-93D3-FC637E1D4AE9Q58583890-0DA8821B-1F1C-41A6-ADAD-4AE1FDDE94A3
P2860
Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Virus-like particle (VLP) lymp ...... munization by different routes
@en
Virus-like particle
@nl
type
label
Virus-like particle (VLP) lymp ...... munization by different routes
@en
Virus-like particle
@nl
prefLabel
Virus-like particle (VLP) lymp ...... munization by different routes
@en
Virus-like particle
@nl
P2093
P2860
P1476
Virus-like particle (VLP) lymp ...... munization by different routes
@en
P2093
Changyi Chen
Eva M Sevick-Muraca
Sheng Zhang
Sunkuk Kwon
P2860
P304
P356
10.1097/CJI.0B013E31818F13C4
P50
P577
2009-02-01T00:00:00Z